These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 29960080)

  • 1. Trabecular bone microarchitecture predicts fragility fractures in postmenopausal women on denosumab treatment.
    Butscheidt S; Rolvien T; Vettorazzi E; Frieling I
    Bone; 2018 Sep; 114():246-251. PubMed ID: 29960080
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of denosumab on trabecular bone score in postmenopausal women with osteoporosis.
    McClung MR; Lippuner K; Brandi ML; Zanchetta JR; Bone HG; Chapurlat R; Hans D; Wang A; Zapalowski C; Libanati C
    Osteoporos Int; 2017 Oct; 28(10):2967-2973. PubMed ID: 28748386
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bone Microarchitecture Assessed by HR-pQCT as Predictor of Fracture Risk in Postmenopausal Women: The OFELY Study.
    Sornay-Rendu E; Boutroy S; Duboeuf F; Chapurlat RD
    J Bone Miner Res; 2017 Jun; 32(6):1243-1251. PubMed ID: 28276092
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Individual trabecula segmentation (ITS)-based morphological analyses and microfinite element analysis of HR-pQCT images discriminate postmenopausal fragility fractures independent of DXA measurements.
    Liu XS; Stein EM; Zhou B; Zhang CA; Nickolas TL; Cohen A; Thomas V; McMahon DJ; Cosman F; Nieves J; Shane E; Guo XE
    J Bone Miner Res; 2012 Feb; 27(2):263-72. PubMed ID: 22072446
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alterations of cortical and trabecular architecture are associated with fractures in postmenopausal women, partially independent of decreased BMD measured by DXA: the OFELY study.
    Sornay-Rendu E; Boutroy S; Munoz F; Delmas PD
    J Bone Miner Res; 2007 Mar; 22(3):425-33. PubMed ID: 17181395
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lower Bone Density, Impaired Microarchitecture, and Strength Predict Future Fragility Fracture in Postmenopausal Women: 5-Year Follow-up of the Calgary CaMos Cohort.
    Burt LA; Manske SL; Hanley DA; Boyd SK
    J Bone Miner Res; 2018 Apr; 33(4):589-597. PubMed ID: 29363165
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Deterioration of trabecular plate-rod and cortical microarchitecture and reduced bone stiffness at distal radius and tibia in postmenopausal women with vertebral fractures.
    Wang J; Stein EM; Zhou B; Nishiyama KK; Yu YE; Shane E; Guo XE
    Bone; 2016 Jul; 88():39-46. PubMed ID: 27083398
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of moderate/severe vertebral fractures with reduced trabecular volumetric bone density in older women and reduced areal femoral neck bone density in older men from the community: A cross-sectional study (SPAH).
    Torres GHF; Guzman LFE; Alvarenga JC; Lopes NHM; Pereira RMR
    Maturitas; 2019 Feb; 120():61-67. PubMed ID: 30583766
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Persistence at 24 months with denosumab among postmenopausal women with osteoporosis: results of a prospective cohort study.
    Silverman SL; Siris E; Belazi D; Recknor C; Papaioannou A; Brown JP; Gold DT; Lewiecki EM; Quinn G; Balasubramanian A; Yue S; Stolshek B; Kendler DL
    Arch Osteoporos; 2018 Aug; 13(1):85. PubMed ID: 30088189
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Compartment-specific effects of muscle strength on bone microarchitecture in women at high risk of osteoporosis.
    Simon A; Schäfer HS; Schmidt FN; Stürznickel J; Amling M; Rolvien T
    J Cachexia Sarcopenia Muscle; 2022 Oct; 13(5):2310-2321. PubMed ID: 35852049
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Changes in cortical microarchitecture are independent of areal bone mineral density in patients with fragility fractures.
    Mussawy H; Ferrari G; Schmidt FN; Schmidt T; Rolvien T; Hischke S; Rüther W; Amling M
    Injury; 2017 Nov; 48(11):2461-2465. PubMed ID: 28882378
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of Teriparatide, Denosumab, or Both on Spine Trabecular Microarchitecture in DATA-Switch: a Randomized Controlled Trial.
    Tsai JN; Jiang LA; Lee H; Hans D; Leder BZ
    J Clin Densitom; 2017; 20(4):507-512. PubMed ID: 28624340
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Microarchitecture and Peripheral BMD are Impaired in Postmenopausal White Women With Fracture Independently of Total Hip T-Score: An International Multicenter Study.
    Boutroy S; Khosla S; Sornay-Rendu E; Zanchetta MB; McMahon DJ; Zhang CA; Chapurlat RD; Zanchetta J; Stein EM; Bogado C; Majumdar S; Burghardt AJ; Shane E
    J Bone Miner Res; 2016 Jun; 31(6):1158-66. PubMed ID: 26818785
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Longitudinal evaluation of the effects of alendronate on MRI bone microarchitecture in postmenopausal osteopenic women.
    Folkesson J; Goldenstein J; Carballido-Gamio J; Kazakia G; Burghardt AJ; Rodriguez A; Krug R; de Papp AE; Link TM; Majumdar S
    Bone; 2011 Mar; 48(3):611-21. PubMed ID: 21059422
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Peripheral Quantitative Computed Tomography (pQCT) Measures Contribute to the Understanding of Bone Fragility in Older Patients With Low-trauma Fracture.
    Jiang H; Yates CJ; Gorelik A; Kale A; Song Q; Wark JD
    J Clin Densitom; 2018; 21(1):140-147. PubMed ID: 28285742
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment with denosumab reduces secondary fracture risk in women with postmenopausal osteoporosis.
    Palacios S; Kalouche-Khalil L; Rizzoli R; Zapalowski C; Resch H; Adachi JD; Gallagher JC; Feldman RG; Kendler DL; Wang A; Wagman RB; Adami S
    Climacteric; 2015; 18(6):805-12. PubMed ID: 26029985
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of 8 or 5 years of denosumab treatment in postmenopausal women with osteoporosis: results from the FREEDOM Extension study.
    Papapoulos S; Lippuner K; Roux C; Lin CJ; Kendler DL; Lewiecki EM; Brandi ML; Czerwiński E; Franek E; Lakatos P; Mautalen C; Minisola S; Reginster JY; Jensen S; Daizadeh NS; Wang A; Gavin M; Libanati C; Wagman RB; Bone HG
    Osteoporos Int; 2015 Dec; 26(12):2773-83. PubMed ID: 26202488
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Denosumab or oral bisphosphonates in primary osteoporosis: a "real-life" study.
    Cairoli E; Palmieri S; Goggi G; Roggero L; Arosio M; Chiodini I; Eller-Vainicher C
    J Endocrinol Invest; 2018 Aug; 41(8):1005-1013. PubMed ID: 29340971
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vivo assessment of trabecular bone microarchitecture by high-resolution peripheral quantitative computed tomography.
    Boutroy S; Bouxsein ML; Munoz F; Delmas PD
    J Clin Endocrinol Metab; 2005 Dec; 90(12):6508-15. PubMed ID: 16189253
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Denosumab for prevention of fractures in postmenopausal women with osteoporosis.
    Cummings SR; San Martin J; McClung MR; Siris ES; Eastell R; Reid IR; Delmas P; Zoog HB; Austin M; Wang A; Kutilek S; Adami S; Zanchetta J; Libanati C; Siddhanti S; Christiansen C;
    N Engl J Med; 2009 Aug; 361(8):756-65. PubMed ID: 19671655
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.